Switching from Keppra® to generic Levetiracetam

Description

This leaflet is designed to inform patients about why they may receive a generic version of their epilepsy medication (levetiracetam) instead of the branded version (Keppra®), and to provide reassurance about the safety and effectiveness of the switch.

What the Leaflet is About

The leaflet explains:

That Keppra® is a branded version of levetiracetam, a Category 3 epilepsy medicine.
According to MHRA guidance, switching between different versions of Category 3 epilepsy medicines is generally safe.
Why patients might be given a different version (e.g. cost savings, supply issues).
That all generic versions contain the same active ingredient, though some inactive ingredients and appearance (size, shape, taste, coating) may vary.
The possibility of side effects or breakthrough seizures when switching, although these are rare.
The importance of discussing any concerns or seizure changes with a healthcare professional.

Who it is For

The leaflet is intended for:

Patients with epilepsy who are currently prescribed Keppra®.
Carers or parents of patients who may be affected by the switch.
Healthcare professionals looking for a simple way to explain the rationale behind switching to generics.

Attached Files

File	Action
363507_1_0 Keppra Switch_S.pdf	Download